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Introduction: Bronchiectasis (BC) is a multidimensional and etiologically diverse disease and,
therefore, no single parameter can be used to determine its overall severity and prognosis. In
this regard, two different validated scores are currently used to assess the severity of non-cystic
fibrosis bronchiectasis (NCFB): the FACED score and the Bronchiectasis Severity Index (BSI).
Objective: To describe the etiology of NCFB and compare the results of the assessment of NCFB
severity obtained via FACED and BSI scores.
Methods: Retrospective study of demographic and clinical data of a convenience sample of
NCFB patients attending the Functional Breathing Re-adaptation appointment at the Pneumol-
ogy B Unit, University Hospital Center of Coimbra. All patients underwent evaluation of the
variables incorporated in the FACED score (FEV1% predicted, age, chronic colonization by Pseu-
domonas aeruginosa, radiological extent of the disease, and dyspnea) and in the BSI (age, body
mass index, FEV1% predicted, hospitalization and exacerbations before study, dyspnea, chronic
colonization by P. aeruginosa and other microrganisms, and radiological extent of the disease).





Results: The sample included 40 patients, 22 females and 18 males, aged 39--87 years.
Regarding the etiology of NCFB, we found: idiopathic (60%), post-infectious (20%), sequelae
of pulmonary tuberculosis (12.5%) and primary immunodeficiency related (7.5%).
According to the FACED score we found 20 patients (50%) with mild BC, 15 patients (37.5%)
with moderate and 5 patients (12.5%) with severe BC. The frequency of patients with low,
intermediate and high BSI was 13 (32.5%), 13 (32.5%) and 14 (35%), respectively in relation
to derived BSI, Moreover, we observed a weak but statistically significant association between
FACED and BSI scores: Fisher’s exact test (p = 0.004), tau-b de Kendall (0.469; p = 0.001). The
Kappa test (0.330; p = 0.002) also shows us that there is 55% agreement between the two scales.
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Conclusion: There is a small but significant correlation between the two scales: a tendency
is observed for patients to be classified with a higher BSI compared to the FACED score. This
can be explained by the fact that BSI (and not FACED) evaluates parameters including BMI,
hospitalization and exacerbations before study, chronic colonization by other microorganisms
and development of cystic bronchiectasis. Further studies should address how these scores may
impact clinical practice.
© 2017 Sociedade Portuguesa de Pneumologia. Published by Elsevier España, S.L.U. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
Introduction
Bronchiectasis (BC) is a chronic respiratory disease char-
acterized by abnormal and irreversible dilatation of the
airways, associated with a vicious cycle of compromised host
defenses, inflammation, chronic colonization with bacteria
and recurrent infection with progressive bronchial lesion.1,2
Traditionally, bronchiectasis is classified as cystic fibrosis-
related bronchiectasis and non-cystic fibrosis bronchiectasis
(NCFB). Cystic fibrosis-related bronchiectasis affects a small
homogeneous population of patients, where respiratory dis-
ease is the main predictor of mortality,3 whereas NCFB
affects a heterogeneous population of patients with diverse
etiologies.3 These may result from various hereditary or
acquired local or systemic diseases, and often the etiological
diagnosis is not defined even after exhaustive assessment.1
The clinical course of this pathology is unpredictable. While
the usual disease progression is slow, cases involving faster
disease progression have been reported.4 Bronchiectasis is
also associated with chronic sputum, multiple exacerbations
and dyspnea, which progressively worsened quality of life5,6
and lung function (annual loss of about 50 ml in FEV1),7 with
a negative impact on the number of hospitalizations, health
costs and mortality.8
As it is a chronic and progressive disease, the establish-
ment of management strategies is essential for the control
of this pathology. Several individual variables were used
to assess the severity of NCFB, but the prognosis cannot
be adequately assessed through a single variable analy-
sis.
Recently, two multidimensional severity indexes were
developed: the FACED score and the Bronchiectasis Sever-
ity Index (BSI). The FACED score corresponds to a scale
that evaluates the severity and prognosis of NCFB through
the analysis of five parameters/variables: functional (FEV1%
predicted), physiological (age), microbiological (chronic
colonization by Pseudomonas aeruginosa), radiological
(number of lobes affected) and clinician (degree of dyspnea,
evaluated by the mMRC scale).9 The BSI corresponds to a
scale that evaluates the severity and prognosis of NCFB by
analyzing nine parameters/variables: age, body mass index
(BMI), FEV1% predicted, hospitalization and exacerbations
before study, degree of dyspnea, chronic colonization by
P. aeruginosa and other microorganisms and radiological
extension of the disease.2
Methods
Objective
The present study aimed at describing the etiology of NCFB
and comparing the results of the evaluation of the severity
of NCFB via FACED and BSI scores.
Study design
Retrospective study of demographic and clinical data of
a convenience sample of NCFB patients attending the
Functional Breathing Re-adaptation appointment at the
Pneumology B Unit, Coimbra University Hospital Center.
Sample
Included 40 patients (22 females, 18 males) aged 39--87
years.
Inclusion criteria were: patients with NCFB who had not
used antibiotics in the previous 4 weeks. Disease diagno-
sis was established according to current recommendations
after high resolution computed tomography of the tho-
rax in patients with clinical presentation consistent with
BC.10
Excluded from the study were patients with active
malignant neoplasia, cystic fibrosis, active mycobacterial
infection, HIV, primary diagnosis of pulmonary fibro-
sis/sarcoidosis, secondary traction bronchiectasis and those
who received long-term antibiotic therapy prior to the start
of the study.
Clinical assessments and calculation of severity
scores
Patients were assessed and managed according to the British
Thoracic Society (BTS) guidelines.10 The underlying eti-
ology of bronchiectasis was determined following testing
recommended by BTS guidelines.10 All patients underwent
evaluation of the variables incorporated in the FACED and
BSI scores, in the last appointment. Patients were classified
according to severity cut-offs described in original publica-
tions.
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The FACED score
This score incorporates 5 dicotomic variables (Appendix
A). The total score is calculated by summing the scores
for each variable and can range from 0 to 7 points. This
score classifies bronchiectasis into three severity classes:
mild bronchiectasis (global score 0--2 points), moder-
ate bronchiectasis (global score 3--4 points), and severe
bronchiectasis (global score 5--7 points).
BSI score
This score incorporates 9 variables (Appendix B). The total
score is calculated by summing the scores for each variable
and can range from 0 to 26 points. According to the over-
all score, patients are classified into three classes: patients
with low BSI score (0--4 points), intermediate BSI score (5--8
points), high BSI score (≥9 points).
Analysis of patients in the sample
The severity of dyspnea was assessed according to the
mMRC/MRC breathlessness scale into 5◦: grade 0/1 (patient
is not troubled by breathlessness except on strenuous exer-
cise), grade I/2 (getting short breath when hurrying on the
level or walking up a slight hill), grade II/3 (walking slower
than most people of the same age due to dyspnea or hav-
ing to stop to breathe after walking 15 min on foot at own
pace), grade III/4 (stopping for breath after walking about
100 m or after a few minutes on level ground), grade IV/5
(being too breathless to leave the house or being breathless
when undressing).11,12
All patients underwent spirometry. Spirometry results
were expressed as % predicted.
Bacteriological study of sputum was performed on
spontaneous samples collected in the morning.13 Chronic
colonization was defined by the isolation of potentially
pathogenic bacteria in sputum culture on two or more occa-
sions, at least 3 months apart in a 1-year period. The
predominant pathogen was the organism grown most fre-
quently. Patients were asked to provide sputum samples at
least twice a year at clinical reviews. Patients who were
unable to provide sputum samples (for example due to lack
of productive cough) were classified as non-colonized.14,15
The radiological evaluation represents the extent of
bronchiectasis according to the number of lung lobes
affected (the lingula was considered as independent lobe)
and the degree of bronchial dilation (tubular, varicose or
cystic). A small bronchiectasis visible only in a single pul-
monary segment was not considered, as this may appear in
a significant proportion of healthy individuals.14--16
Hospitalization for severe acute exacerbations was
defined according to the guidelines of the British Tho-
racic Society.10 Exacerbations were defined according to
the British Thoracic Society as an acute aggravation with
increased purulence and volume of sputum and/or systemic
symptoms.10
Statistical analysis
A descriptive analysis of the quantitative variables was per-
formed, and is represented as means and standard deviation
(mean ± SD). When applicable, normality was verified with
the Kolmogorov--Smirnov (K--S) test with Lilliefors correc-
tion. For the categorical variables, absolute frequencies and
percentages in relation to the total and conditioned were
obtained.
The statistical treatment of the data was performed





Fisher’s exact test (chi-square test not adequate for the sam-
ple size), the Wilcoxon test for paired samples and the Kappa
Cohen test were used to analyze the data. All hypothesis
tests were considered significant whenever their respective
test value (p-value, p) did not exceed the significance level
of 5%.
Results
The characteristics of the patients included in the study are
described in Table 1. In terms of the etiology of NCFB, data
analysis revealed that 24 patients (60%) were idiopathic, 8
(20%) post-infectious, 5 (12.5%) with sequelae of pulmonary
tuberculosis and 3 patients (5%) with primary immunodefi-
ciencies.
The FACED and BSI score variables are shown in
Tables 2 and 3 (respectively). After applying the FACED
score, 20 patients (50%) were classified as mild BC, 15
(37.5%) as moderate and 5 (12.5%) as severe BC. When using
Table 1 Characterization of study participants.
Characteristics Sample (n = 40)
Sex 18♂; 22 ♀
Age (mean ± SD) (years) (K--S p-value) 65.9 ± 14.1 (p = 0.072)
Body Mass Index (mean ± SD) (kg/m2) (K--S p-value) 26.2 ± 5.6 (p > 0.200)
Dyspnea MRC (median) 3
Dyspnea mMRC (median) 2
FEV1% predicted (mean ± SD) (K--S p-value) 63.4 ± 22.1 (p > 0.200)
Pseudomonas aeruginosa colonization (n (%)) 5 (12.5%)
Colonization with other microorganisms (n (%)) 4 (10%)
Number of affected lobes (mean ± SD) (K--S p-value) 3.6 ± 1.4 (p < 0.001)
Exacerbations in previous year (mean ± SD) (K--S p-value) 1.2 ± 1.5 (p = 0.003)
Hospital admission in the preceding 2 years (mean ± SD) (K--S p-value) 0.7 ± 1.6 (p < 0.001)
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Table 2 Values of FACED score variables.










Radiological extension of the disease -- no. affected lobes
>2 involved lobes 32 (80%)
≤2 involved lobes 8 (20%)
Dyspnea -- mMRC
>II (III and IV) 5 (12.5%)
≤II (0--II) 35 (87.5%)
the BSI score, 13 patients (32.5%) were classified as low BSI,
13 (32.5%) as intermediate BSI and 14 (35%) as high BSI.
Statistical analysis was also performed to assess how the
scores match in predicting BC severity (% conditioned by
each of the scores). As demonstrated in Table 4, 30.8% of
patients with intermediate BSI were found to have mild BC
by FACED and 78.6% of patients with high BSI had mild or
moderate BC by FACED. Moreover, 40% of patients with mild
BC by FACED had at least moderate BSI and about 46.7% of
patients with moderated BC by FACED had elevated BSI.
A weak but statistically significant association between
FACED and BSI scores was also detected using Fisher’s exact
test (p = 0.004) and tau-b de Kendall (0.469; p = 0.001). Upon
applying the Wilcoxon test for paired samples, it was found
that the two scales were significantly different (p = 0.004),
with the BSI scale showing the highest scores (Table 4). With
this test, a 55.0% agreement between the two scales (22
ties/40 = 0.55) was also detected (Table 4). Similarly, using
the Cohen’s Kappa test ( = 0.330, p = 0.002) a 55.0% agree-
ment between the two scales was also found.
Discussion
Currently, the medical community faces two major chal-
lenges in the management of bronchiectasis: (1) identifying
patients with a high symptom burden, those at risk of fre-
quent exacerbations or rapid lung function decline, who may
benefit from aggressive treatment at an early stage of the
disease, in order to reduce the associated complications as
well as allow a closer follow-up at a specialized center and
(2) identifying low-risk patients, who could be suitable for
non-specialist follow-up or simpler treatment regimes, to
reduce health costs and improve patient satisfaction.
At present, there are two scales that can be used to
assess the severity and the prognosis of the NCFB: FACED
and BSI. Both scales have clear advantages and disadvan-
tages. The FACED score is easy to obtain, calculate and
interpret as it incorporates five dichotomous variables. The
BSI is a relatively more complex scale since it incorporates
nine variables with different values for each. Both strat-
ify patients into severity risk categories in order to predict
Table 3 Values of BSI score variables.














Hospital admission in the preceding 2 years
No 29 (72.5%)
Yes 11 (27.5%
Exacerbations in previous year
0--2 35 (87.5%)
≥3 5 (12.5%)







Colonization with other microorganisms
No 36 (90%)
Yes 4 (10%)




the likelihood of mortality. Moreover, these two scales have
also different objectives: while the FACED was developed
specifically to predict the likelihood of mortality in five year
follow-up of NCFB of any etiology, thus providing a quick
assessment of the initial severity, the BSI was developed to
predict mortality, severe exacerbations requiring hospital-
ization, frequency of exacerbations, and quality of life.
As a multidimensional and heterogeneity disease,
bronchiectasis is not a disease of which impact is primar-
ily measured in terms of mortality. In this context, although
the FACED score has demonstrated a great prognostic capac-
ity in the evaluation of bronchiectasis, it does not include
the number or severity of exacerbations so, in order to eval-
uate the predictive capacity of exacerbations and mortality,
a new scale, E-FACED,17 was recently constructed and vali-
dated. This score significantly increases the FACED capacity
to predict future yearly exacerbations while maintaining the
score’s simplicity and prognostic capacity for death.17
A observational prospective study by McDonnell et al.
(2016), developed to compare the predictive utility of
BSI and FACED in assessing clinically relevant disease out-
comes across seven European cohorts with 1612 patients,
demonstrated that both tools accurately predict mortality
The Bronchiectasis Severity Index and FACED score 153
Table 4 % conditioned and Wilcoxon test for paired samples.
% score FACED conditioned by BSI score
Low BSI Intermediate BSI High BSI
FACED Mild bronchiectasis 92.3% 30.8% 28.6%
Moderate bronchiectasis 7.7% 53.8% 50.0%
Severe bronchiectasis 0.0% 15.4% 21.4%
% score BSI conditioned hair score FACED
Mild bronchiectasis Moderate bronchiectasis Severe bronchiectasis
BSI Low BSI 60.0% 6.6% 0.0%
Intermediate BSI 20.0% 46.7% 40.0%
High BSI 20.0% 46.7% 60.0%
Wilcoxon test for paired samples N
BSI -- FACED Positive ranks (BSI > FACED) 15
Negative ranks (BSI < FACED) 3
Ties (BSI = FACED) 22
Total 40
in bronchiectasis, but that the BSI is superior to FACED in
predicting multiple clinically useful outcomes including hos-
pital admissions, exacerbations, quality of life, respiratory
symptoms, exercise capacity and lung function decline.18
A retrospective study by Ellis et al. (2016), developed
to assess the ability of these scores to predict long-term
mortality in a cohort of 91 patients, showed that both
scoring systems had similar predictive power for 5-year
mortality.19 In addition, both scores were able to predict 15-
year mortality providing further validation for the prediction
of mortality in bronchiectasis and demonstrating their util-
ity over a longer period than originally described. However,
the predictive capacity of FACED was superior for 15-year
mortality.19
In our study, we found a small but significant associ-
ation between the two scales, since there is a tendency
for patients to be classified with a higher BSI relative to
the FACED. This could be explained by the fact that the
BSI (and not FACED) assesses parameters including BMI,
hospitalization and exacerbations before study, chronic col-
onization by other microorganisms and development of
cystic bronchiectasis. The fact that BSI score performs a dif-
ferent stratification of the parameters age, dyspnea degree
and FEV1% predicted can also be a contributing factor.
This study has limitations that must be mentioned. The
limited number of patients, the fact that these scores
applied to the last appointment and there have been no
deaths until now, did not provide for a more exhaustive
analyses, specifically the capacity of these scores to pre-
dict mortality. Despite these limitations, our results are
similar to results from other studies, which show that the
BSI provides an accurate assessment of disease severity
enabling decision-making in terms of identifying high-risk
patients who may benefit from aggressive treatment and
low-risk patients who could receive non-specialist follow-
up or simpler treatment regimes. However, our results do
not prove that implementation of the BSI or FACED may
improve clinical outcomes and further studies are needed to
determine how these scales may have an impact on clinical
practice.
Conclusion
As a multidimensional pathology, the severity and progno-
sis of NCFB cannot be adequately assessed through a single
variable analysis. Thus, although different, the FACED score
and BSI correspond to validated multidimensional indices,
which provide an accurate assessment of the severity and
prognosis of this pathology. In our study, we found a small
but significant association between the two scales, since
there is a tendency for patients to be classified with higher
BSI relative to the FACED. The currently available literature
shows that the BSI is superior to FACED in predicting multi-
ple clinically useful outcomes including hospital admissions,
exacerbations, quality of life, respiratory symptoms, exer-
cise capacity and lung function decline, providing a clinically
relevant assessment of the severity of the disease.
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Appendix A. FACED score
This score incorporates 5 dicotomic variables:
F: FEV1% predicted (forced expiratory volume in first
second): functional evaluation -- cut-off 50% (>50%: 0
points; ≤50%: 2 points).
A: Age: physiological parameter -- cut-off 70 years (≤70: 0
points; >70: 2 points).
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C: Chronic colonization by Pseudomonas aeruginosa:
microbiological parameter -- dicotomic parameter: maxi-
mum value 1 point.
E: Radiological extension of the disease -- number of
affected lobes: radiological evaluation -- cut-off 2 lobes
(≤2 affected lobes: 0 points; >2 affected lobes: 1 point).
D: Dyspnea -- mMRC (modified Medical Research Council
Dyspnea Scale): clinical evaluation -- cut-off grade II of the
mMRC scale (≤II: 0 points; >II: 1 point).
Appendix B. BSI score
This score incorporates 9 variables:
1. Age: <50 years (0 points); 50--69 years (2 points); 70--79
years (4 points); ≥80 years (6 points).
2. Body mass index (BMI): ≥18.5 (0 points); <18.5 (2
points).
3. FEV1% predicted: >80% (0 points); 50--80% (1 point);
30--49% (2 points); <30% (3 points).
4. Hospital admission in the preceding 2 years: No (0
points); Yes (5 points).
5. Exacerbations in the previous year: 0--2 (0 points); ≥3
(2 points).
6. Medical Research Council Dyspnea Scale (MRC): 1--3 (0
points); 4 (2 points); 5 (3 points).
7. Pseudomonas aeruginosa colonization: No (0 point);
Yes (3 points).
8. Colonization with other microorganisms: No (0 point);
Yes (1 point).
9. Radiological extension (≥3 involved lobes or cystic
bronchiectasis): No (0 points); Yes (1 point).
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